drugset / Trial / NCT06736704

SNV4818 in Participants With Advanced Solid Tumors

NCT06736704

Phase 1/2 Recruiting 320 enrolled Pikavation Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

Timeline

Start
2025-02-20
Primary completion
2027-04
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SNV4818 Unknown Oral
Background Fulvestrant Small molecule 500 mg Intramuscular
Background Palbociclib Small molecule 125 mg Oral

Indications